Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014

Vaccine

Volumn 33, Issue 31, 2015, Pages 3605-3608

  Girard, Marc P ^a   Picot, Valentina ^b   Longuet, Christophe ^b   Nabel, Gary J ^c  

^a ACADÉMIE NATIONALE DE MÉDECINE   (France)

^b Fondation Mérieux Applied Research   (France)

^c Sanofi   (United States)

Author keywords

HIV; Immunoprophylaxis; Neutralizing antibodies; Passive immunization; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; B LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; CHEMOPROPHYLAXIS; CROSS PROTECTION; DISEASE MODEL; FRANCE; HIV INFECTIONS; PROCEDURES; TREATMENT OUTCOME;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CHEMOPREVENTION; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FRANCE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; TREATMENT OUTCOME;

EID: 84937643307     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.004     Document Type: Conference Paper

References (29)

1. Fauci A.S., Marston H.D. Ending AIDS - is an HIV vaccine necessary?. N Engl J Med 2014, 3707:495-498.
2. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
3. Liao H.K., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., et al. Co-evolution of a broadly neutralizing HIV-1 neutralizing antibody and founder virus. Nature 2013, 496:469-476.
4. Barouch D.H., Stephenson K.E., Borducchi E.N., Smith K., Stanley K., McNally A.G., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013, 155:531-539.
5. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structure, and B cell ontogenies. Immunity 2012, 37:412-425.
6. Huang J., Doria-Rose N.A., Longo N.S., Laub L., Lin C.L., Turk E., et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat Protoc 2013, 8:1907-1915.
7. Scheid J.F., Mouquet H., Feldham N., Seaman M.S., Velinzon K., Pietzsch J., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
8. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
9. Huang J., Kang B.H., Pancera M., Lee J.H., Tong T., Feng Y., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
10. Mascola J.R., Haynes B.F. HIV neutralizing antibodies: understanding nature's pathways. Immunol Rev 2013, 254:225-244.
11. Bonsignori M., Wiehe K., Grimm S.K., Lynch R., Yang G., Kozink D.M., et al. An autoreactive antibody from a systemic lupus erythematous/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 2014, 124:1835-1843.
12. Hraber P., Seaman M.S., Bailer R.T., Mascola J.R., Montefiori D.C., Korber B.T. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014, 28:163-169.
13. Doria-Rose N.A., Schramm C.A., Gorman J., Moore P.L., Bhiman J.N., Dekosky B.J., et al. Development pathway for potent V1V2-directed HIV-neutralizing antibody. Nature 2014, 509:55-62.
14. Wibmer C.K., Bhiman J.N., Gray E.S., Tumba N., Abdool Karim S.S., Williamson C., et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013, 9:1-16.
15. Munro J.B., Gorman J., Ma X., Zhou Z., Arthos J., Burton D.R., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014, 346:759-763.
16. Yasmeen A., Ringe R., Derking R., Cupo A., Julien J.P., Burton D.R., et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins and monomeric subunits. Retrovirology 2014, 10.1186/1742-4690-11-41.
17. McGuire A.T., Glenn J.A., Lippy A., Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 2014, 88:2645-2657.
18. Jardine S., Julien J.P., Manis S., Ota T., Kalyuzhniy O., McGuire A., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
19. Rudicell R.S., Kwon Y.D., Ko S.Y., Pegu A., Louder M.K., Georgiev I.S., et al. Enhanced potency of broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014, 88:12669-12682.
20. Ko S.Y., Pequ A., Rudicell R.S., Yang Z.Y., Joyce M.G., Chen X., et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014, 514:642-645.
21. Shingai M., Nishimura Y., Klein F., Mouquet H., Donau O.K., Plishka R., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viremia. Nature 2013, 503:277-280.
22. Balazs A.B., Ouyang Y., Hong C.M., Chen J., Nguyen S.M., Rao D.S., et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014, 20:296-300.
23. Balazs A.B., Bloom J.D., Hong C.M., Rao D.S., Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 2013, 31:647-652.
24. Deal C., Balazs A.B., Espinoza D.A., Zavala F., Baltimore D., Ketner G. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite infection in mice. Proc Natl Acad Sci U S A 2014, 111:12528-12533.
25. Goo L., Chohan V., Nduati R., Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 2014, 20:655-658.
26. Girard M.P., Picot V., Longuet C., Nabel G.J. Report of the Cent Gardes HIV Vaccine Conference on the B-cell response to HIV. Part 1: broadly neutralizing antibodies. Vaccine 2013.
27. Corey L., McElrath M.J. One shot forward for HIV prevention. Nat Med 2014, 20:241-242.
28. Haynes B.F., Gilbert P.D., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
29. Roederer M., Keele B.F., Schmidt S.D., Mason R.D., Wells H.C., Fischer W., et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014, 505:502-508.